Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy [Medical Sciences]
| Publication Date: |
2018-03-14
|
|---|---|
| Publisher: |
National Academy of Sciences
|
| Print ISSN: |
0027-8424
|
| Electronic ISSN: |
1091-6490
|
| Topics: |
Biology
Medicine
Natural Sciences in General
|
| Published by: |
| _version_ | 1836398844215033856 |
|---|---|
| autor | Konstantinos V. Floros, Timothy L. Lochmann, Bin Hu, Carles Monterrubio, Mark T. Hughes, Jason D. Wells, Cristina Bernado Morales, Maninderȷit S. Ghotra, Carlotta Costa, Andrew J. Souers, Sosipatros A. Boikos, Joel D. Leverson, Ming Tan, Violeta Serra, Jennifer E. Koblinski, Joaquin Arribas, Aleix Prat, Laia Pare, Todd W. Miller, Mikhail G. Dozmorov, Hisashi Harada, Brad E. Windle, Maurizio Scaltriti, Anthony C. Faber |
| beschreibung | HER2 (ERBB2) amplification is a driving oncogenic event in breast cancer. Clinical trials have consistently shown the benefit of HER2 inhibitors (HER2i) in treating patients with both local and advanced HER2+ breast cancer. Despite this benefit, their efficacy as single agents is limited, unlike the robust responses to other receptor... |
| citation_standardnr | 6205521 |
| datenlieferant | ipn_articles |
| feed_id | 113 |
| feed_publisher | National Academy of Sciences |
| feed_publisher_url | http://www.nasonline.org/ |
| insertion_date | 2018-03-14 |
| journaleissn | 1091-6490 |
| journalissn | 0027-8424 |
| publikationsjahr_anzeige | 2018 |
| publikationsjahr_facette | 2018 |
| publikationsjahr_intervall | 7984:2015-2019 |
| publikationsjahr_sort | 2018 |
| publisher | National Academy of Sciences |
| quelle | PNAS - Proceedings of the National Academy of Sciences |
| relation | http://www.pnas.org/content/115/11/E2594.short?rss=1 |
| search_space | articles |
| shingle_author_1 | Konstantinos V. Floros, Timothy L. Lochmann, Bin Hu, Carles Monterrubio, Mark T. Hughes, Jason D. Wells, Cristina Bernado Morales, Maninderȷit S. Ghotra, Carlotta Costa, Andrew J. Souers, Sosipatros A. Boikos, Joel D. Leverson, Ming Tan, Violeta Serra, Jennifer E. Koblinski, Joaquin Arribas, Aleix Prat, Laia Pare, Todd W. Miller, Mikhail G. Dozmorov, Hisashi Harada, Brad E. Windle, Maurizio Scaltriti, Anthony C. Faber |
| shingle_author_2 | Konstantinos V. Floros, Timothy L. Lochmann, Bin Hu, Carles Monterrubio, Mark T. Hughes, Jason D. Wells, Cristina Bernado Morales, Maninderȷit S. Ghotra, Carlotta Costa, Andrew J. Souers, Sosipatros A. Boikos, Joel D. Leverson, Ming Tan, Violeta Serra, Jennifer E. Koblinski, Joaquin Arribas, Aleix Prat, Laia Pare, Todd W. Miller, Mikhail G. Dozmorov, Hisashi Harada, Brad E. Windle, Maurizio Scaltriti, Anthony C. Faber |
| shingle_author_3 | Konstantinos V. Floros, Timothy L. Lochmann, Bin Hu, Carles Monterrubio, Mark T. Hughes, Jason D. Wells, Cristina Bernado Morales, Maninderȷit S. Ghotra, Carlotta Costa, Andrew J. Souers, Sosipatros A. Boikos, Joel D. Leverson, Ming Tan, Violeta Serra, Jennifer E. Koblinski, Joaquin Arribas, Aleix Prat, Laia Pare, Todd W. Miller, Mikhail G. Dozmorov, Hisashi Harada, Brad E. Windle, Maurizio Scaltriti, Anthony C. Faber |
| shingle_author_4 | Konstantinos V. Floros, Timothy L. Lochmann, Bin Hu, Carles Monterrubio, Mark T. Hughes, Jason D. Wells, Cristina Bernado Morales, Maninderȷit S. Ghotra, Carlotta Costa, Andrew J. Souers, Sosipatros A. Boikos, Joel D. Leverson, Ming Tan, Violeta Serra, Jennifer E. Koblinski, Joaquin Arribas, Aleix Prat, Laia Pare, Todd W. Miller, Mikhail G. Dozmorov, Hisashi Harada, Brad E. Windle, Maurizio Scaltriti, Anthony C. Faber |
| shingle_catch_all_1 | Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy [Medical Sciences] HER2 (ERBB2) amplification is a driving oncogenic event in breast cancer. Clinical trials have consistently shown the benefit of HER2 inhibitors (HER2i) in treating patients with both local and advanced HER2+ breast cancer. Despite this benefit, their efficacy as single agents is limited, unlike the robust responses to other receptor... Konstantinos V. Floros, Timothy L. Lochmann, Bin Hu, Carles Monterrubio, Mark T. Hughes, Jason D. Wells, Cristina Bernado Morales, Maninderȷit S. Ghotra, Carlotta Costa, Andrew J. Souers, Sosipatros A. Boikos, Joel D. Leverson, Ming Tan, Violeta Serra, Jennifer E. Koblinski, Joaquin Arribas, Aleix Prat, Laia Pare, Todd W. Miller, Mikhail G. Dozmorov, Hisashi Harada, Brad E. Windle, Maurizio Scaltriti, Anthony C. Faber National Academy of Sciences 0027-8424 00278424 1091-6490 10916490 |
| shingle_catch_all_2 | Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy [Medical Sciences] HER2 (ERBB2) amplification is a driving oncogenic event in breast cancer. Clinical trials have consistently shown the benefit of HER2 inhibitors (HER2i) in treating patients with both local and advanced HER2+ breast cancer. Despite this benefit, their efficacy as single agents is limited, unlike the robust responses to other receptor... Konstantinos V. Floros, Timothy L. Lochmann, Bin Hu, Carles Monterrubio, Mark T. Hughes, Jason D. Wells, Cristina Bernado Morales, Maninderȷit S. Ghotra, Carlotta Costa, Andrew J. Souers, Sosipatros A. Boikos, Joel D. Leverson, Ming Tan, Violeta Serra, Jennifer E. Koblinski, Joaquin Arribas, Aleix Prat, Laia Pare, Todd W. Miller, Mikhail G. Dozmorov, Hisashi Harada, Brad E. Windle, Maurizio Scaltriti, Anthony C. Faber National Academy of Sciences 0027-8424 00278424 1091-6490 10916490 |
| shingle_catch_all_3 | Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy [Medical Sciences] HER2 (ERBB2) amplification is a driving oncogenic event in breast cancer. Clinical trials have consistently shown the benefit of HER2 inhibitors (HER2i) in treating patients with both local and advanced HER2+ breast cancer. Despite this benefit, their efficacy as single agents is limited, unlike the robust responses to other receptor... Konstantinos V. Floros, Timothy L. Lochmann, Bin Hu, Carles Monterrubio, Mark T. Hughes, Jason D. Wells, Cristina Bernado Morales, Maninderȷit S. Ghotra, Carlotta Costa, Andrew J. Souers, Sosipatros A. Boikos, Joel D. Leverson, Ming Tan, Violeta Serra, Jennifer E. Koblinski, Joaquin Arribas, Aleix Prat, Laia Pare, Todd W. Miller, Mikhail G. Dozmorov, Hisashi Harada, Brad E. Windle, Maurizio Scaltriti, Anthony C. Faber National Academy of Sciences 0027-8424 00278424 1091-6490 10916490 |
| shingle_catch_all_4 | Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy [Medical Sciences] HER2 (ERBB2) amplification is a driving oncogenic event in breast cancer. Clinical trials have consistently shown the benefit of HER2 inhibitors (HER2i) in treating patients with both local and advanced HER2+ breast cancer. Despite this benefit, their efficacy as single agents is limited, unlike the robust responses to other receptor... Konstantinos V. Floros, Timothy L. Lochmann, Bin Hu, Carles Monterrubio, Mark T. Hughes, Jason D. Wells, Cristina Bernado Morales, Maninderȷit S. Ghotra, Carlotta Costa, Andrew J. Souers, Sosipatros A. Boikos, Joel D. Leverson, Ming Tan, Violeta Serra, Jennifer E. Koblinski, Joaquin Arribas, Aleix Prat, Laia Pare, Todd W. Miller, Mikhail G. Dozmorov, Hisashi Harada, Brad E. Windle, Maurizio Scaltriti, Anthony C. Faber National Academy of Sciences 0027-8424 00278424 1091-6490 10916490 |
| shingle_title_1 | Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy [Medical Sciences] |
| shingle_title_2 | Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy [Medical Sciences] |
| shingle_title_3 | Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy [Medical Sciences] |
| shingle_title_4 | Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy [Medical Sciences] |
| timestamp | 2025-06-30T23:33:32.318Z |
| titel | Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy [Medical Sciences] |
| titel_suche | Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy [Medical Sciences] |
| topic | W WW-YZ TA-TD |
| uid | ipn_articles_6205521 |